September 11, 2024 4:36 PM
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial
Novo Nordisk said on Wednesday that its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects. The maker of blockbuster drugs Wegovy and Ozempic said in March that a Phase I trial of the pill version of amycretin showed participants lost up to 13.1% of their weight after 12 weeks, prompting shares to surge more than 8%. That compared to weight loss of about 6% after 12 weeks and 15% after 68 we...